Search Results for "Sun Damage"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Sun Damage. Results 1 to 10 of 23 total matches.
Masoprocol for Multiple Actinic Keratoses
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993 (Issue 907)
, sometimes occurring as solitary lesions or in small numbers, but when sun damage is severe, the number ...
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
Sunscreens
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
, penetrates the dermis and
causes long-term damage. UVB, which is mostly
absorbed in the epidermis ...
Excessive exposure to ultraviolet (UV) radiation can
cause erythema, photoaging, and skin cancer.
Sunscreens are widely used to reduce these risks, but
questions remain about their effectiveness and safety.
In 2021, the FDA proposed a rule that would require
additional safety studies for some sunscreen active
ingredients and mandate better UVA protection in
sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102 doi:10.58347/tml.2025.1731a | Show Introduction Hide Introduction
Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
up 95% of terrestrial UV radiation,
penetrates the dermis and causes long-term damage.
UVB, which ...
In June 2021, the FDA approved the IV amyloid beta-directed
monoclonal antibody aducanumab (Aduhelm) for treatment
of Alzheimer’s disease. The approval did not restrict use of
the drug to patients with mild cognitive impairment or mild
dementia, which was the population enrolled in the clinical
trials. Now, Biogen, with the permission of the FDA, has made
an addition to the labeling of the drug that says: Treatment with
Aduhelm should be initiated in patients with mild cognitive
impairment or mild dementia stage of disease, the population
in which treatment was initiated in clinical...
Prevention and Treatment of Sunburn
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004 (Issue 1184)
block at least part of UVA II in addition to UVB.
SUN AVOIDANCE — Avoiding exposure to direct sunlight ...
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part of UVA II in addition to UVB.
Click here to view the free full article.
Click here to view the free full article.
A New Sunscreen Agent
The Medical Letter on Drugs and Therapeutics • May 20, 2007 (Issue 1261)
erythemogenic. Both UVA and UVB can
damage DNA, suppress immune function and cause
skin cancer in animals.
1 ...
Ecamsule (terephthalylidene dicamphor sulfonic acid), the first new sunscreen agent to be approved by the FDA in 18 years, is now available in the US in a moisturizer called Anthelios SX. Ecamsule has been used in Canada and Europe for more than 10 years.
Tretinoin for Photodamaged Skin
The Medical Letter on Drugs and Therapeutics • Mar 20, 1992 (Issue 866)
been used to improve the appearance of skin damaged by chronic exposure to the sun, although not approved ...
Tretinoin (tret' i noyn; all-trans-retinoic acid; Retin-A), a derivative of vitamin A, has been used for years for topical treatment of acne. More recently, it has also been used to improve the appearance of skin damaged by chronic exposure to the sun, although not approved for this indication by the US Food and Drug Administration.
Shade UVAGuard - A Second Broad-Spectrum Sunscreen
The Medical Letter on Drugs and Therapeutics • Jun 11, 1993 (Issue 898)
UVAGuard appears to have no advantage over Photoplex in preventing damage from the sun. Whether either ...
In 1989, Photoplex (Allergan Herbert), a combination of the dibenzoyl methane avobenzone (Parsol 1789) and the aminobenzoic acid (PABA) ester padimate O, was the first 'broad spectrum' sunscreen to become available in the USA (Medical Letter, 31:59, 1989). Now, Shade UVAGuard (Schering-Plough), a similar product, has been approved by the US Food and Drug Administration; it also contains avobenzone, plus the benzophenone oxybenzone and octyl methoxycinnamate.
Topical Drugs for Aging Skin
The Medical Letter on Drugs and Therapeutics • Aug 15, 1997 (Issue 1007)
for years to treat skin damaged by
chronic exposure to the sun (Medical Letter, 34:28, 1992). First ...
Topical tretinoin (all-trans-retinoic acid) has been used for years to treat skin damaged by chronic exposure to the sun (Medical Letter, 34:28, 1992). First approved by the FDA only for treatment of acne in concentrations ranging from 0.025% to 0.1% (Retin-A, and others), it has now been approved as an 0.05% formulation in an emollient cream base (Renova) for topical treatment of photodamaged skin. In recent years, alpha-hydroxy acids incorporated in some cosmetics have also been promoted as effective in improving the appearance of aging skin.
Photoplex - A Broad Spectrum Sunscreen
The Medical Letter on Drugs and Therapeutics • Jun 16, 1989 (Issue 794)
photosensitivity reactions, but
also contributes to chronic skin damage and can cause sunburn.
SUNSCREENS ...
Photoplex (Herbert), a new sunscreen formulation containing 7% padimate O and 3% Parsol 1789, is being advertised as the first and only chemical sunscreen with proven absorption throughout the UVB and UVA spectrum.
In Brief: Calcium and Vitamin D Supplements
The Medical Letter on Drugs and Therapeutics • Jul 31, 2006 (Issue 1240)
years old and 600 IU for those over 70. But
those infrequently exposed to the sun may need 8001000 IU ...
The results of a randomized, placebo-controlled trial of calcium and vitamin D supplements in more than 36,000 postmenopausal women, conducted as part of the Women’s Health Initiative (RD Jackson et al. N Engl J Med 2006; 354:669), have been misinterpreted by some patients to mean that they should stop taking such supplements.At the time of recruitment, the participants in this study had an average daily calcium intake of 1100-1200 mg. They were randomized to take either 1000 mg of calcium carbonate plus 400 IU of vitamin D3 or a placebo for an average of 7 years. Both groups were permitted...